Our study suggests that PGCC appears in an early stage not related to the appearance of neuroendocrine phenotype, a finding that deserves additional research on the status of androgen receptor, most probably placing PGCC as an androgen-indifferent status prostate cancer or as a transitive status from androgen indifferent to androgen-independent status prostate cancer [4, 8]. The gene discussed is AR; the disease is prostate carcinoma.